Julio Duarte, PharmD, PhD, FAHA
Professional Interests
Research & Expertise:
Biography
Dr. Julio Duarte is a professor in the Division of Pharmacy Practice and Science. He previously served as associate professor of pharmacy and medicine, co-director of the UF Center for Pharmacogenomics and Precision Medicine and the Debbie DeSantis Term Professor at the University of Florida (UF) College of Pharmacy. He earned both his PharmD and PhD in clinical pharmaceutical sciences from the University of Florida.
Before joining UF, Dr. Duarte was an assistant professor at the University of Illinois Chicago (UIC) and co-director of the University of Illinois Hospital Personalized Medicine Program. He has served as a grant reviewer for the National Institutes of Health (NIH), National Science Foundation (NSF), American Heart Association and U.S. Department of Defense. An elected Fellow of the American Heart Association, Dr. Duarte has received research awards from both UIC and UF.
Education
- 2010-2011 - Postdoctoral Associate – University of Florida College of Pharmacy
- 2010 - PhD, Clinical Pharmaceutical Sciences, University of Florida College of Pharmacy
- 2006 - PharmD, University of Florida College of Pharmacy
- 2002 - AA, University of Florida College of Liberal Arts and Sciences
Honors
- 2024 - Teaching and Service Award, University of Florida College of Pharmacy
- 2023 - Faculty Diversity, Inclusion, and Health Equity Award, University of Florida College of Pharmacy
- 2023 - Outstanding Teaching Team – Year 3, University of Florida College of Pharmacy
- 2017 - Elected Fellow of the American Heart Association
- 2017 - Outstanding Clinical Science Research Award, University of Florida College of Pharmacy
- 2015-2017 - NIH Clinical Research Loan Repayment Program Awardee (NHLBI)
- 2015 - Finalist, Award for Excellence in Medication Safety, American Society of Health‑System Pharmacists Foundation (for the UIC Personalized Medicine Program)
- 2013 - Hans W. Vahlteich Research Scholar, University of Illinois Chicago
Publications
- Machine Learning Prediction of Pharmacogenetic Testing Uptake Among Opioid-Prescribed Patients Using Electronic Health Records: Retrospective Cohort Study, JMIR Medical Informatics. 2026 Jan | journal-article. doi: 10.2196/81048.
- Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy, Clinical Pharmacology & Therapeutics. 2025 Dec | journal-article. doi: 10.1002/cpt.70071.
- CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy, Journal of the American Heart Association. 2025 Jul | journal-article. doi: 10.1161/JAHA.125.041634.
- Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module, Clinical Pharmacology & Therapeutics. 2025 Jun | journal-article. doi: 10.1002/cpt.3599.
- Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel, Clinical and Translational Science. 2025 May | journal-article. doi: 10.1111/cts.70230.
- Disparities in Clinical Outcomes Observed Within Electronic Health Record Data From a Statewide Cohort of Pulmonary Arterial Hypertension Patients, Pulmonary Circulation. 2025 Jan | journal-article. doi: 10.1002/pul2.70041.
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy, Clinical Pharmacology & Therapeutics. 2024 Oct | journal-article. doi: 10.1002/cpt.3351.
- Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR, Clinical Pharmacology & Therapeutics. 2024 Sep | journal-article. doi: 10.1002/cpt.3274.
- Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction, Clinical Pharmacology & Therapeutics. 2024 Jul | journal-article. doi: 10.1002/cpt.3385.
- CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention, Journal of the American Heart Association. 2024 Jun | journal-article. doi: 10.1161/JAHA.123.033791.
- Using Omics to Identify Novel Therapeutic Targets in Heart Failure, Circulation: Genomic and Precision Medicine. 2024 Jun | journal-article. doi: 10.1161/CIRCGEN.123.004398.
- Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients, Clinical and Translational Science. 2024 Jan | journal-article. doi: 10.1111/cts.13692.
- Pharmacist-Guided Pharmacogenetic Service Lowered Warfarin-Related Hospitalizations, Pharmacogenomics. 2023 Apr | journal-article. doi: 10.2217/pgs-2023-0014.
- An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers, Clinical Pharmacology and Therapeutics. 2023 Jan | journal-article. doi: 10.1002/cpt.2957.
- Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention, Clinical Pharmacology and Therapeutics. 2023 Jan | journal-article. doi: 10.1002/cpt.2776.
- Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved, Frontiers in Genetics. 2023 Jan | journal-article. doi: 10.3389/fgene.2022.1085994.
- CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings, Journal of the American Heart Association. 2022 Feb | journal-article. doi: 10.1161/JAHA.121.024159.
- Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers, The Pharmacogenomics Journal. 2022 Feb | journal-article. doi: 10.1038/s41397-021-00257-1.
- Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing, Pharmacogenomics. 2022 Jan | journal-article. doi: 10.2217/pgs-2021-0109.
- Patients’ Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination, Journal of Personalized Medicine. 2022 Jan | journal-article. doi: 10.3390/jpm12122046.
- Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease, American Heart Journal Plus: Cardiology Research and Practice. 2022 Jan | journal-article. doi: 10.1016/j.ahjo.2022.100152.
- β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery, Clinical and Translational Science. 2022 Jan | journal-article. doi: 10.1111/cts.13178.
- Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing, Genetics in Medicine. 2021 Dec | journal-article. doi: 10.1038/s41436-021-01269-9.
- Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease, Journal of the American Heart Association. 2021 Jun | journal-article. doi: 10.1161/JAHA.120.020633.
- County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States, Scientific Reports. 2021 Jan | journal-article. doi: 10.1038/s41598-021-82384-0.
- Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects, Frontiers in Genetics. 2021 Jan | journal-article. doi: 10.3389/fgene.2021.701405.
- IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias, Blood. 2021 Jan | journal-article. doi: 10.1182/blood.2020005944.
- Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention, Clinical Pharmacology and Therapeutics. 2021 Jan | journal-article. doi: 10.1002/cpt.2039.
- NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial, Pharmacotherapy. 2021 Jan | journal-article. doi: 10.1002/phar.2626.
- Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.13032.
- Pharmacogenetics to guide cardiovascular drug therapy, Nature Reviews Cardiology. 2021 Jan | journal-article. doi: 10.1038/s41569-021-00549-w.
- Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population, Journal of cardiovascular pharmacology. 2020 Jan | journal-article. doi: 10.1097/FJC.0000000000000779.
- Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data, Pharmacogenomics Journal. 2020 Jan | journal-article. doi: 10.1038/s41397-020-0162-5.
- County-Level Longitudinal Clustering of COVID-19 Mortality to Incidence Ratio in the United States, Research Square. 2020 Jan | other. doi: 10.21203/rs.3.rs-40632/v2.
- Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue, Clinical and Translational Science. 2019 Jan | journal-article. doi: 10.1111/cts.12632.
- Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension, Scientific Reports. 2019 Jan | journal-article. doi: 10.1038/s41598-019-55700-y.
- Association of Genetic Variants with Warfarin-Associated Bleeding among Patients of African Descent, JAMA - Journal of the American Medical Association. 2018 Jan | journal-article. doi: 10.1001/jama.2018.14955.
- CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue, Clinical Pharmacology and Therapeutics. 2018 Jan | journal-article. doi: 10.1002/cpt.1032.
- Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients, Pulmonary Circulation. 2018 Jan | journal-article. doi: 10.1177/2045894018773049.
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention, JACC: Cardiovascular Interventions. 2018 Jan | journal-article. doi: 10.1016/j.jcin.2017.07.022.
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy, Clinical Pharmacology and Therapeutics. 2018 Jan | journal-article. doi: 10.1002/cpt.1006.
- Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach, Clinical Pharmacology and Therapeutics. 2017 Jan | journal-article. doi: 10.1002/cpt.558.
- The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12456.
- Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease, PLOS ONE. 2016 Sep | journal-article. doi: 10.1371/journal.pone.0163013.
- Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure, Journal of Cardiac Failure. 2016 Jan | journal-article. doi: 10.1016/j.cardfail.2015.12.016.
- Clopidogrel pharmacogenetics: From evidence to implementation, Future Cardiology. 2016 Jan | journal-article. doi: 10.2217/fca-2016-0045.
- Implementation of inpatient models of pharmacogenetics programs, American Journal of Health-System Pharmacy. 2016 Jan | journal-article. doi: 10.2146/ajhp150946.
- Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges, Clinical and Translational Science. 2016 Jan | journal-article. doi: 10.1111/cts.12404.
- Genes affecting warfarin response - Interactive or additive?, Journal of Clinical Pharmacology. 2015 Jan | journal-article. doi: 10.1002/jcph.425.
- Pharmacogenomics of Hypertension and Heart Disease, Current Hypertension Reports. 2015 Jan | journal-article. doi: 10.1007/s11906-015-0586-5.
- Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes, Expert Review of Cardiovascular Therapy. 2014 Jan | journal-article. doi: 10.1586/14779072.2014.970180.
- A Look to the Future: Cardiovascular Pharmacoepigenetics, Pharmacogenomics. 2013 Jan | book-chapter. doi: 10.1016/B978-0-12-391918-2.00015-9.
- Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression, Pharmacogenomics Journal. 2013 Jan | journal-article. doi: 10.1038/tpj.2012.4.
- Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics, Journal of Hypertension. 2013 Jan | journal-article. doi: 10.1097/HJH.0b013e32835e2a71.
- Epigenetics primer: Why the clinician should care about epigenetics, Pharmacotherapy. 2013 Jan | journal-article. doi: 10.1002/phar.1325.
- Feasibility of implementing a comprehensive warfarin pharmacogenetics service, Pharmacotherapy. 2013 Jan | journal-article. doi: 10.1002/phar.1329.
- Personalized medicine in cardiology: The time for genotype-guided therapy is now, Future Cardiology. 2013 Jan | journal-article. doi: 10.2217/fca.13.35.
- Pharmacologic treatments for pulmonary hypertension: Exploring pharmacogenomics, Future Cardiology. 2013 Jan | journal-article. doi: 10.2217/fca.13.6.
- Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide, Journal of Translational Medicine. 2012 Jan | journal-article. doi: 10.1186/1479-5876-10-56.
- Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide, Pharmacogenetics and Genomics. 2010 Jan | journal-article. doi: 10.1097/FPC.0b013e32833b5958.
- Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics, Expert Review of Cardiovascular Therapy. 2010 Jan | journal-article. doi: 10.1586/erc.10.27.